

# Michael W Fried

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11503401/michael-w-fried-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147  
papers

19,085  
citations

54  
h-index

138  
g-index

156  
ext. papers

20,967  
ext. citations

8.1  
avg, IF

6.24  
L-index

#	Paper	IF	Citations
147	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 975-82	59.2	5551
146	Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2682-95	59.2	1226
145	Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1879-88	59.2	975
144	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , <b>2015</b> , 149, 649-59	13.3	622
143	Response-guided telaprevir combination treatment for hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1014-24	59.2	618
142	Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1099-105	59.2	518
141	Side effects of therapy of hepatitis C and their management. <i>Hepatology</i> , <b>2002</b> , 36, S237-S244	11.2	428
140	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 425-33	13.4	425
139	Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. <i>Gastroenterology</i> , <b>2006</b> , 131, 470-7	13.3	405
138	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2014</b> , 384, 403-13	40	394
137	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. <i>Annals of Internal Medicine</i> , <b>2017</b> , 166, 637-648	8	383
136	Side effects of therapy of hepatitis C and their management. <i>Hepatology</i> , <b>2002</b> , 36, S237-44	11.2	337
135	Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). <i>Journal of Hepatology</i> , <b>2002</b> , 37, 500-6	13.4	337
134	Management of hepatitis C in the hemophilia patient. <i>American Journal of Medicine</i> , <b>1999</b> , 107, 85S-89S	2.4	285
133	Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. <i>Hepatology</i> , <b>2001</b> , 33, 433-8	11.2	269
132	A pilot study of ribavirin therapy for chronic hepatitis C. <i>Hepatology</i> , <b>1992</b> , 16, 649-54	11.2	258
131	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. <i>Hepatology</i> , <b>2013</b> , 58, 1918-29	11.2	233

130	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. <i>Hepatology</i> , <b>2007</b> , 46, 1548-63	11.2	218
129	Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. <i>Liver International</i> , <b>2016</b> , 36, 807-16	7.9	217
128	Side effects of therapy for chronic hepatitis C. <i>Gastroenterology</i> , <b>2003</b> , 124, 1711-9	13.3	212
127	Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. <i>Gastroenterology</i> , <b>2014</b> , 146, 430-41.e6	13.3	193
126	HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , <b>2008</b> , 47, 428-34	11.2	178
125	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. <i>Gastroenterology</i> , <b>2016</b> , 151, 1131-1140.e5	13.3	166
124	Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. <i>Gastroenterology</i> , <b>2010</b> , 139, 1181-9	13.3	156
123	Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. <i>Hepatology</i> , <b>2017</b> , 66, 389-397	11.2	147
122	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , <b>2016</b> , 150, 419-29	13.3	140
121	Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2001</b> , 35, 749-55	13.4	138
120	Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 69-75	13.4	137
119	Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 65-72	4	134
118	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , <b>2017</b> , 66, 1090-1101	11.2	127
117	Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , <b>2016</b> , 150, 684-695.e5	13.3	126
116	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. <i>Hepatology</i> , <b>2011</b> , 53, 32-41	11.2	123
115	Barriers to hepatitis C treatment. <i>Liver International</i> , <b>2012</b> , 32 Suppl 1, 151-6	7.9	122
114	Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 274-82	27.4	103
113	Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. <i>Journal of Clinical Pharmacology</i> , <b>2010</b> , 50, 434-49	2.9	102

112	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. <i>Gut</i> , <b>2015</b> , 64, 1824-33	19.2	99
111	Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. <i>Hepatology</i> , <b>2018</b> , 67, 1253-1260	11.2	97
110	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , <b>2016</b> , 22, 24-33	4.5	96
109	Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. <i>Gastroenterology</i> , <b>2007</b> , 132, 733-44	13.3	94
108	Current therapy for hepatitis C: pegylated interferon and ribavirin. <i>Clinics in Liver Disease</i> , <b>2003</b> , 7, 149-61	4.6	94
107	R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. <i>Hepatology</i> , <b>2008</b> , 48, 385-97	11.2	92
106	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , <b>2015</b> , 64, 948-56	19.2	90
105	Quantitation of pretreatment serum interferon-Inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. <i>Hepatology</i> , <b>2011</b> , 53, 14-22	11.2	86
104	A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. <i>Hepatology</i> , <b>2013</b> , 57, 1325-32	11.2	80
103	Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 286-93	13.4	74
102	Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?. <i>Liver Transplantation</i> , <b>1998</b> , 4, 128-32		74
101	Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1993</b> , 38, 631-6	4	72
100	Social stigmatization and hepatitis C virus infection. <i>Journal of Clinical Gastroenterology</i> , <b>2006</b> , 40, 220-4	3	70
99	Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 183-92	6.9	68
98	The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 1909-16	4	67
97	Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 1298-305	0.7	66
96	Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. <i>Seminars in Liver Disease</i> , <b>2004</b> , 24 Suppl 2, 47-54	7.3	61
95	Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. <i>Hepatology</i> , <b>2008</b> , 48, 1033-43	11.2	59

94	Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. <i>Liver Transplantation</i> , <b>2005</b> , 11, 1235-41	4.5	58
93	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. <i>Gut</i> , <b>2017</b> , 66, 1844-1852	19.2	54
92	A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1777-86	0.7	54
91	American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. <i>Gastroenterology</i> , <b>2017</b> , 152, 1578-1587	13.3	53
90	Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. <i>Hepatology</i> , <b>2002</b> , 36, 967-72	11.2	53
89	A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 3225-9	0.7	49
88	Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1981-8	0.7	48
87	Assessing the validity of self-reported medication adherence in hepatitis C treatment. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 1116-23	2.9	48
86	Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. <i>Gastroenterology</i> , <b>2012</b> , 142, 1314-1323.e1	13.3	46
85	Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2949-58	0.7	45
84	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 540-548	13.4	45
83	Randomized study of asunaprevir plus pegylated interferon- $\alpha$ and ribavirin for previously untreated genotype 1 chronic hepatitis C. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 885-93	1.6	43
82	High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 3251-6	4	43
81	Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 1073-82	2.2	42
80	Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 247-55	2.4	41
79	Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 106-11	13.4	41
78	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 776-783	11.6	37
77	Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 2182-90	4	37

76	A pilot study of 2CQ (didanosine) for the treatment of chronic hepatitis B. <i>Hepatology</i> , <b>1992</b> , 16, 861-41.2	4.1	37
75	Therapy of chronic hepatitis B with a 6-month course of ribavirin. <i>Journal of Hepatology</i> , <b>1994</b> , 21, 145-50.3.4	3.4	33
74	Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1469-74	4	31
73	Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221683	3.7	29
72	Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 6079-92	5.9	28
71	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 486-497	13.4	27
70	Internal biliary stenting in orthotopic liver transplantation. <i>Liver Transplantation</i> , <b>2000</b> , 6, 356-61	4.5	23
69	Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , <b>2013</b> , 81, 361-74	6.5	21
68	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. <i>Gastroenterology</i> , <b>2019</b> , 157, 1506-1517.e1	13.3	19
67	Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , <b>2003</b> , 48, 140-5	4	19
66	Therapy of chronic viral hepatitis. <i>Medical Clinics of North America</i> , <b>1996</b> , 80, 957-72	7	19
65	Unexpected maintenance of hepatitis C viral diversity following liver transplantation. <i>Journal of Virology</i> , <b>2012</b> , 86, 8432-9	6.6	18
64	High relapse rate seen at week 72 for patients treated with R1626 combination therapy. <i>Hepatology</i> , <b>2008</b> , 48, 1349-50	11.2	17
63	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1811-1819.e4	6.9	16
62	An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 254-260	11.6	16
61	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196908	3.7	16
60	Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. <i>Journal of Psychosomatic Research</i> , <b>2011</b> , 71, 349-56	4.1	16
59	Hepatitis C virus: a critical appraisal of approaches to therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 397-414; quiz 366	6.9	16



58	Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance. <i>Gastroenterology</i> , <b>2006</b> , 131, 757-64	13.3	16
57	Guidelines for stopping therapy in chronic hepatitis C. <i>Current Gastroenterology Reports</i> , <b>2004</b> , 6, 17-21	5	16
56	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2541-2551.e2	6.9	15
55	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminaemia. <i>Liver International</i> , <b>2015</b> , 35, 2358-62	7.9	14
54	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. <i>Scientific Reports</i> , <b>2018</b> , 8, 3199	4.9	14
53	Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1439-44	4	14
52	Persistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1794-8	4	14
51	Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. <i>Liver International</i> , <b>2015</b> , 35, 1886-92	7.9	13
50	Optimizing treatment regimens in hepatitis C. <i>Clinics in Liver Disease</i> , <b>2006</b> , 10, 835-50	4.6	13
49	Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. <i>Clinical Trials</i> , <b>2012</b> , 9, 102-12	2.2	12
48	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , <b>2020</b> , 72, 1819-1837	11.2	12
47	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 856-865	3.4	11
46	Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients. <i>PLoS ONE</i> , <b>2013</b> , 8, e69698	3.7	11
45	Hepatitis C and Alcohol: Fundamental and Translational Research Directions. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2003</b> , 27, 726-731	3.7	11
44	Diagnostic testing for hepatitis C: practical considerations. <i>American Journal of Medicine</i> , <b>1999</b> , 107, 31S-35S		11
43	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , <b>2020</b> , 71, 1894-1909	11.2	11
42	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , <b>2017</b> , 57, 58-68	2.3	10
41	Advances in therapy for chronic hepatitis C. <i>Clinics in Liver Disease</i> , <b>2001</b> , 5, 1009-23	4.6	10

40	Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. <i>Hepatology Communications</i> , <b>2018</b> , 2, 354-363	6	9
39	The role of triple therapy in HCV genotype 1-experienced patients. <i>Liver International</i> , <b>2011</b> , 31 Suppl 1, 58-61	7.9	9
38	Clinical application of hepatitis C virus genotyping and quantitation. <i>Clinics in Liver Disease</i> , <b>1997</b> , 1, 631-46	4.6	9
37	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 700-707	13.4	8
36	What's Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment. <i>Patient</i> , <b>2017</b> , 10, 335-344	3.7	8
35	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 35, 1011-1020	4	8
34	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , <b>2021</b> , 73, 2124-2140	11.2	8
33	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , <b>2017</b> , 186, 356-366	3.8	7
32	Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49, 336-44	3	6
31	A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale. <i>Hepatology Communications</i> , <b>2018</b> , 2, 484-491	6	6
30	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 72, 73-85	2.3	6
29	Treatment options of patients with chronic hepatitis C who have failed prior therapy. <i>Clinical Liver Disease</i> , <b>2016</b> , 7, 40-44	2.2	6
28	Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 457-468	6.1	5
27	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1388-1399	6	5
26	Hepatitis C infection with normal liver chemistry tests. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 503-5	6.9	5
25	Viral factors affecting the outcome of therapy for chronic hepatitis C. <i>Reviews in Gastroenterological Disorders</i> , <b>2004</b> , 4 Suppl 1, S8-S13		5
24	Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C. <i>Pilot and Feasibility Studies</i> , <b>2018</b> , 4, 92	1.9	4
23	Hepatitis C virus: a critical appraisal of new approaches to therapy. <i>Hepatitis Research and Treatment</i> , <b>2012</b> , 2012, 138302		4



22	HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , <b>2016</b> , 36, 488-502	7.9	4
21	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , <b>2021</b> , 73, 1637-1651	11.2	4
20	Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C. <i>Contemporary Clinical Trials Communications</i> , <b>2017</b> , 6, 85-96	1.8	3
19	Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz175	1	3
18	Hepatitis C viral infection in patients with hemophilia and hemolytic disorders. <i>Clinical Liver Disease</i> , <b>2012</b> , 1, 95-97	2.2	3
17	Hepatitis C: current options for nonresponders to peginterferon and ribavirin. <i>Current Gastroenterology Reports</i> , <b>2008</b> , 10, 53-9	5	3
16	Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem. <i>Infection Control and Hospital Epidemiology</i> , <b>2016</b> , 37, 140-2	2	3
15	"If I Get Cured, My Whole Quality of Life Will Change": Patients Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	3
14	High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. <i>Liver International</i> , <b>2016</b> , 36, 344-52	7.9	2
13	Chronic hepatitis B virus mono-infection at a university hospital in Zambia. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 622-628	3.4	2
12	Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1042-1056	3.4	2
11	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , <b>2021</b> , 41, 692-704	7.9	2
10	Controversies in hepatitis C therapy: Reactivation of hepatitis B virus. <i>Clinical Liver Disease</i> , <b>2017</b> , 10, 87-92	2.2	1
9	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 259-261	6.9	1
8	Linkage of resistance-associated substitutions in GT1 sofosbuvir± NS5A inhibitor failures treated with glecaprevir/pibrentasvir. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 820-828	13.4	1
7	Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy. <i>BMC Infectious Diseases</i> , <b>2020</b> , 20, 632	4	0
6	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , <b>2021</b> , 74, 2952-2964	11.2	0
5	Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment. <i>Liver International</i> , <b>2011</b> , 31, 903-4	7.9	

4	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS[COC13 HEPAVIH)". <i>Journal of Hepatology</i> , <b>2020</b> , 72, 592-593	13.4
3	Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients awaiting a liver transplant". <i>Journal of Hepatology</i> , <b>2020</b> , 73, 985-986	13.4
2	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. <i>GastroHep</i> , <b>2021</b> , 3, 196-208	1
1	Real-World Evidence and Hepatitis C. <i>Topics in Medicinal Chemistry</i> , <b>2019</b> , 411-427	0.4